Abstract:HIV-1 based lentiviral viruses are considered powerful and versatile gene therapy vectors to deliver therapeutic genes to patients with hereditary or acquired diseases. These vectors can efficiently transduce a variety of cell types when dividing or non-dividing to provide permanent delivery and long-term gene expression. Demand for scalable manufacturing protocols able to generate enough high titre vector for widespread use of this technology is increasing and considerable efforts to improve vector production cost-effectively, is ongoing. Current methods for LV production mainly use transient transfection of producer cell lines. Cells can be grown at scale, either in 2D relying on culturing producer cells in multi-tray flask cell culture factories or in roller bottles or can be adapted to grow in 3D suspensions in large batch fermenters. This suits rapid production and testing of new vector constructs pre-clinically for their efficacy, particle titre and safety. In this study, we sought to improve lentiviral titre over time by testing two alternative commercially available transfection reagents Fugene® 6 and Genejuice® with the commonly used polycation, polyethyleneimine. Our aim was to identify less cytotoxic transfection reagents that could be used to generate LV particles at high titre past the often used 72 hour period when vector is usually collected before producer cell death is caused due to post transfection cytotoxicity. We show that LV could be produced in extended culture using Genejuice® and even by transfected cells in glass flasks in suspension. Because this delivery agent is less toxic to 293T producer cells, following optimisation of transfection we found that LV can be harvested for more than 10 days at high titre. Using our protocol, titres of 10 9 TU/ml and 10 8 TU/ml were routinely reached via traditional monolayer conditions or suspension cultures, respectively. We propose, this simple change in vector production enables large volumes of high titre vector to be produced, cost effectively for non-clinical in vivo and in vitro applications or for more stringent downstream clinical grade vector purification.

Efficient lentiviral transduction of different human and mouse cells

Optimised protocols to generate high titre lentiviral vectors using a novel transfection agent enabling extended HEK293T culture following transient transfection and suspension culture

Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells.

Efficient gene transfer mediated by HIV-1-based defective lentivector and inhibition of HIV-1 replication

Optimized protocol for high‐titer lentivirus production and transduction of primary fibroblasts

Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors

[High-titer preparation of HIV-1-based defective lentivector and it mediated efficient gene transfer]

Engineering of HEK293T Cell Factory for Lentiviral Production by High-Throughput Selected Genes

Quantitative assessment on the cloning efficiencies of lentiviral transfer vectors with a unique clone site

A new method to efficiently produce transgenic embryos and mice from low-titer lentiviral vectors

A Scalable Lentiviral Vector Production and Purification Method Using Mustang Q Chromatography and Tangential Flow Filtration

Development of a laboratory scalable process for enhancing lentivirus production by transient transfection of HEK293 adherent cultures

A Quantitative Model for Efficient Construction of Lentiviral Vectors with a Unique Clone Site

Optimization of lentiviral vectors generation for biomedical and clinical research purposes: contemporary trends in technology development and applications

Enhanced lentiviral gene delivery to mammalian cells via paired cell surface and viral envelope engineering

An Enhanced Retroviral Vector for Efficient Genetic Manipulation and Selection in Mammalian Cells

Optimization of lentiviral vector production for scale-up in fixed-bed bioreactor

Production of Lentiviral Vectors Using a HEK-293 Producer Cell Line and Advanced Perfusion Processing

Continuous Manufacturing of Lentiviral Vectors using a Stable Producer Cell Line in a Fixed-Bed Bioreactor

An efficient low cost means of biophysical gene transfection in primary cells

Exploring nutrient supplementation and bioprocess optimization to improve the production of lentiviral vectors in serum‐free medium suspension cultures